IKT

MKT CAP:$135M

Inhibikase Therapeutics, Inc.

Market Cap

$135M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.65-$0.30 (-15.38%)

Apr 21, 2026

Company Details

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009...

CEO

Christopher H. Cabell

IPO Date

Dec 23, 2020

Website

www.inhibikase.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$48M

EPS (Diluted)

-$0.49

Free Cash Flow

-$28M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 13, 2026

PENDING

FY 2025

Mar 26, 2026

$0EPS -$0.49

Q4 2025

Mar 26, 2026

$0EPS -$0.10

Q3 2025

Nov 14, 2025

$0EPS -$0.13

Q2 2025

Aug 14, 2025

$0EPS -$0.11

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$46.0K	-$3M	-$5M
Q2 22	$6.6K	-$3M	-$5M
Q3 22	$7.3K	$5.6K	-$5M
Q4 22	$63.6K	$58.5K	-$4M
Q1 23	$64.5K	$59.5K	-$5M
Q2 23	$116.4K	-$42.8K	-$6M
Q3 23	$79.6K	$73.0K	-$5M
Q4 23	$1	-$6.6K	-$4M
Q1 24	$0	-$6.6K	-$5M
Q2 24	$0	-$6.6K	-$5M
Q3 24	$0	-$6.6K	-$6M
Q4 24	$0	-$6.6K	-$13M
Q1 25	$0	-$12.7K	-$15M
Q2 25	$0	-$24.2K	-$11M
Q3 25	$0	-$23.7K	-$13M
Q4 25	$0	-$36.8K	-$7M

Valuation

Quarter	P/S	P/E
Q1 22	19.6x	—
Q2 22	56.0x	—
Q3 22	368.0x	—
Q4 22	129.3x	—
Q1 23	136.6x	—
Q2 23	75.5x	—
Q3 23	26.3x	—
Q4 23	34.1x	—
Q1 24	83.1x	—
Q2 24	138.4x	—
Q3 24	90171170.0x	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$4M	-$4M
Q2 22	-$4M	-$4M
Q3 22	-$6M	-$6M
Q4 22	-$4M	-$4M
Q1 23	-$6M	-$6M
Q2 23	-$5M	-$5M
Q3 23	-$4M	-$4M
Q4 23	-$3M	-$3M
Q1 24	-$4M	-$4M
Q2 24	-$5M	-$5M
Q3 24	-$5M	-$5M
Q4 24	-$5M	-$5M
Q1 25	-$4M	-$4M
Q2 25	-$6M	-$6M
Q3 25	-$11M	-$11M
Q4 25	-$8M	-$8M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$43.1K
Q3 22	$200.2K
Q4 22	$0
Q1 23	$0
Q2 23	$14.2K
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$452.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-96.7%	+16.2%
Q2 22	-99.5%	+16.4%
Q3 22	-97.8%	-5.8%
Q4 22	+3169.9%	-12.8%
Q1 23	+40.2%	+2.0%
Q2 23	+1676.7%	+36.0%
Q3 23	+991.3%	+7.3%
Q4 23	-100.0%	+0.1%
Q1 24	-100.0%	+0.1%
Q2 24	-100.0%	-20.1%
Q3 24	-100.0%	+20.2%
Q4 24	-100.0%	+193.6%
Q1 25	—	+205.2%
Q2 25	—	+114.5%
Q3 25	—	+127.6%
Q4 25	—	-43.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$123.2K	267.7%
Q2 22	$132.8K	2026.4%
Q3 22	$101.8K	1396.1%
Q4 22	$100.4K	157.9%
Q1 23	$123.3K	191.1%
Q2 23	$124.8K	107.2%
Q3 23	$129.8K	163.1%
Q4 23	$122.2K	12224900.0%
Q1 24	$53.4K	—
Q2 24	$30.7K	—
Q3 24	$148.0K	—
Q4 24	$8M	—
Q1 25	$2M	—
Q2 25	$4M	—
Q3 25	$0	—
Q4 25	$5M	—

OpEx Breakdown

Quarter	R&D	SG&A
Q1 22	$3M	—
Q2 22	$3M	—
Q3 22	$3M	$2M
Q4 22	$3M	$1M
Q1 23	$3M	$2M
Q2 23	$5M	$2M
Q3 23	$3M	$2M
Q4 23	$3M	$1M
Q1 24	$3M	$2M
Q2 24	$3M	$2M
Q3 24	$4M	$2M
Q4 24	$7M	$6M
Q1 25	$11M	$5M
Q2 25	$5M	$6M
Q3 25	$8M	$6M
Q4 25	$6M	$7M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$37M	$0	$37M
Q2 22	$32M	$0	$32M
Q3 22	$6M	$21M	$27M
Q4 22	$7M	$16M	$23M
Q1 23	$4M	$22M	$26M
Q2 23	$2M	$19M	$21M
Q3 23	$15M	$2M	$17M
Q4 23	$9M	$4M	$13M
Q1 24	$2M	$7M	$10M
Q2 24	$3M	$5M	$8M
Q3 24	$913.4K	$2M	$3M
Q4 24	$56M	$41M	$98M
Q1 25	$73M	$20M	$93M
Q2 25	$78M	$10M	$88M
Q3 25	$38M	$39M	$77M
Q4 25	$139M	$40M	$179M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	4M	-0.1%	+150.7%
Q2 22	4M	+0.6%	+107.0%
Q3 22	4M	-0.5%	+0.3%
Q4 22	4M	0.0%	-0.0%
Q1 23	5M	+9.0%	+9.1%
Q2 23	5M	+14.0%	+23.7%
Q3 23	5M	+2.2%	+27.1%
Q4 23	6M	+15.8%	+47.1%
Q1 24	6M	+2.5%	+38.3%
Q2 24	8M	+18.8%	+44.2%
Q3 24	9M	+17.9%	+66.3%
Q4 24	69M	+680.9%	+1021.2%
Q1 25	90M	+29.1%	+1312.1%
Q2 25	90M	+0.5%	+1094.4%
Q3 25	90M	+0.0%	+913.8%
Q4 25	98M	+9.2%	+41.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$7.7K	6
Q2 22	$1.1K	6
Q3 22	$1.2K	6
Q4 22	$10.6K	6
Q1 23	$10.8K	6
Q2 23	$19.4K	6
Q3 23	$13.3K	6
Q4 23	$0	8
Q1 24	$0	8
Q2 24	$0	8
Q3 24	$0	8
Q4 24	$0	15
Q1 25	$0	15
Q2 25	$0	15
Q3 25	$0	15
Q4 25	$0	50

Revenue / Employee